$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

$imuc Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000162828016021194 Filed on November 10, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.950M	$910.0K	$1.890M
YoY Change	3.17%	-20.87%	105.43%
% of Gross Profit
Research & Development	$5.370M	$4.564M	$4.070M
YoY Change	31.94%	71.42%	208.33%
% of Gross Profit
Depreciation & Amortization	$20.00K	$17.26K	$20.00K
YoY Change	0.0%	146.62%	100.0%
% of Gross Profit
Operating Expenses	$7.320M	$5.472M	$5.280M
YoY Change	38.64%	46.09%	135.71%
Operating Profit		-$5.472M
YoY Change		46.09%
Interest Expense	$990.0K	$342.3K	$470.0K
YoY Change	110.64%		327.27%
% of Operating Profit
Other Income/Expense, Net			-$680.0K
YoY Change
Pretax Income	-$6.320M	-$4.798M	-$4.810M
YoY Change	31.39%	41.06%	125.82%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.320M	-$4.798M	-$4.810M
YoY Change	31.39%	41.06%	126.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.780M	-$1.584M	-$2.128M
COMMON SHARES
Basic Shares Outstanding	137.8M shares	127.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.44M	$15.30M	$22.60M
YoY Change	-49.38%	-37.4%	-2.67%
Cash & Equivalents	$11.44M	$15.30M	$22.60M
Short-Term Investments
Other Short-Term Assets	$791.5K	$631.2K	$797.4K
YoY Change	-0.74%	-52.54%	-34.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$13.41M	$16.97M	$24.56M
YoY Change	-45.38%	-34.15%	0.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$109.8K	$126.7K	$180.9K
YoY Change	-39.3%	-36.64%	281.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.370M	$5.140M	$5.340M
YoY Change	-36.89%	5.11%	815.22%
Total Long-Term Assets	$3.475M	$5.262M	$5.522M
YoY Change	-37.06%	3.47%	649.85%
TOTAL ASSETS
Total Short-Term Assets	$13.41M	$16.97M	$24.56M
Total Long-Term Assets	$3.475M	$5.262M	$5.522M
Total Assets	$16.89M	$22.23M	$30.08M
YoY Change	-43.85%	-27.95%	19.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.342M	$471.6K	$1.161M
YoY Change	15.58%	-45.16%	260.64%
Accrued Expenses	$787.0K	$902.6K	$317.7K
YoY Change	147.74%	-21.52%	-49.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.239M	$1.733M	$2.269M
YoY Change	42.72%	-13.33%	76.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.520M	$8.860M	$6.090M
YoY Change	23.48%	246.09%	915.0%
Total Long-Term Liabilities	$7.520M	$8.860M	$6.090M
YoY Change	23.48%	246.09%	915.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.239M	$1.733M	$2.269M
Total Long-Term Liabilities	$7.520M	$8.860M	$6.090M
Total Liabilities	$10.76M	$10.60M	$8.362M
YoY Change	28.66%	132.4%	343.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$96.22M	-$89.90M	-$74.14M
YoY Change	29.79%		20.85%
Common Stock	$102.4M	$101.5M	$95.85M
YoY Change	6.79%		13.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.132M	$11.63M	$21.72M
YoY Change
Total Liabilities & Shareholders Equity	$16.89M	$22.23M	$30.08M
YoY Change	-43.85%	-27.95%	19.48%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	-$6.320M	-$4.798M	-$4.810M
YoY Change	31.39%	41.06%	126.12%
Depreciation, Depletion And Amortization	$20.00K	$17.26K	$20.00K
YoY Change	0.0%	146.62%	100.0%
Cash From Operating Activities	-$3.740M	-$4.930M	-$5.820M
YoY Change	-35.74%	-21.87%	175.83%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-120.0K	8.280M	3.980M
YoY Change	-103.02%	82700.0%	119.89%
NET CHANGE
Cash From Operating Activities	-3.740M	-4.930M	-5.820M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	-120.0K	8.280M	3.980M
Net Change In Cash	-3.860M	3.350M	-1.840M
YoY Change	109.78%	-151.86%	513.33%
FREE CASH FLOW
Cash From Operating Activities	-$3.740M	-$4.930M	-$5.820M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$3.740M	-$4.930M	-$5.820M
YoY Change	-35.74%	-19.84%	175.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000822411
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	137795802	shares
	dei	Entity Registrant Name EntityRegistrantName	ImmunoCellular Therapeutics, Ltd.
	dei	Trading Symbol TradingSymbol	IMUC
	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.12
	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.07
CY2015Q3	imuc	Charge To Financing Expense ChargeToFinancingExpense	0	USD
	imuc	Charge To Financing Expense ChargeToFinancingExpense	88939	USD
CY2016Q3	imuc	Charge To Financing Expense ChargeToFinancingExpense	111557	USD
	imuc	Charge To Financing Expense ChargeToFinancingExpense	142788	USD
CY2015Q1	imuc	Common Stock Of Public Offering CommonStockOfPublicOffering	3666836	shares
CY2014Q4	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2949867	shares
CY2012Q4	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2823670	shares
CY2016Q1	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	3666836	shares
CY2016Q1	imuc	Common Stock Value Authorizedto Issue CommonStockValueAuthorizedtoIssue	15081494	USD
CY2016Q3	imuc	Common Stock Value Availablefor Sale Under Agreement CommonStockValueAvailableforSaleUnderAgreement	14300000	USD
	imuc	Financing Costs Incurredbut Notyet Paid FinancingCostsIncurredbutNotyetPaid	0	USD
	imuc	Financing Costs Incurredbut Notyet Paid FinancingCostsIncurredbutNotyetPaid	75000	USD
	imuc	Initial Valuation Of Warrants InitialValuationOfWarrants	2476790	USD
	imuc	Issuance Of Warrants And Effect Of Repricing IssuanceOfWarrantsAndEffectOfRepricing	4286314	USD
	imuc	Issuance Of Warrants And Effect Of Repricing IssuanceOfWarrantsAndEffectOfRepricing	2427183	USD
	imuc	Minimum Percentage Of Fair Market Value Of Common Stock MinimumPercentageOfFairMarketValueOfCommonStock	less than 110%
	imuc	Minimum Percentageof Fair Market Valueof Common Stock Percent MinimumPercentageofFairMarketValueofCommonStockPercent	1.1
	imuc	Percentage Of Common Stock Voting Rights Held PercentageOfCommonStockVotingRightsHeld	more than 10%
	imuc	Percentage Of Fair Market Value Of Common Stock PercentageOfFairMarketValueOfCommonStock	not be less than 100%
	imuc	Percentageof Common Stock Voting Rights Held Percent PercentageofCommonStockVotingRightsHeldPercent	0.1
	imuc	Percentageof Fair Market Valueof Common Stock Percent PercentageofFairMarketValueofCommonStockPercent	1
	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	14606377	USD
	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	6629619	USD
	imuc	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	0	USD
	imuc	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	1500000	USD
	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2016Q1	imuc	Stock Offering Maximum Public Float StockOfferingMaximumPublicFloat	75000000	USD
	imuc	Stockand Warrants Issued During Period Value Issuedfor Cash StockandWarrantsIssuedDuringPeriodValueIssuedforCash	4270224	USD
	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	2328298	USD
	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	2045082	USD
CY2010Q2	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2011Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2012Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
	imuc	Warrants Exercised WarrantsExercised	0	USD
	imuc	Warrants Exercised WarrantsExercised	0	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1161258	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	471645	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	317653	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	902573	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	191089	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	249308	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	95849005	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	101516114	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	759424	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-48977	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38890839	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	76688998	shares
CY2015Q4	us-gaap	Assets Assets	30082374	USD
CY2016Q3	us-gaap	Assets Assets	22228777	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	24560538	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	16966339	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23222296	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24435152	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22604481	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15297823	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1212856	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7306658	USD
CY2015Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	21818229	USD
CY2016Q3	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	7457067	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.79
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.50
CY2012Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.87
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.44
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10000000	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	249000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	249000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90310149	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	137795802	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90310149	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	137795802	shares
CY2016Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	21855320	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	9031	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	13780	USD
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	48977	USD
CY2016Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20091036	USD
CY2016Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25136992	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2599308	USD
CY2016Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2903078	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22690344	USD
CY2016Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28040070	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2015Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4176280	USD
CY2016Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3520885	USD
CY2015Q3	us-gaap	Depreciation Depreciation	6997	USD
	us-gaap	Depreciation Depreciation	20282	USD
CY2016Q3	us-gaap	Depreciation Depreciation	17256	USD
	us-gaap	Depreciation Depreciation	58219	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.28
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.33
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	790487	USD
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	359219	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P20M
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1200000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2015Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	339136	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2328298	USD
CY2016Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1118411	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2045082	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1083516	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3206356	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	908380	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3058027	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3401255	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7980831	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4797825	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15760741	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	535594	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-764613	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	26449	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	584920	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	4060977	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-655395	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	153690	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-431268	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	889146	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	354142	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-166200	USD
	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	0	USD
	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	377837	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	342323	USD
	us-gaap	Interest Expense InterestExpense	889146	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5498	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	14408	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	9920	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	18831	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	8554	USD
CY2015Q4	us-gaap	Liabilities Liabilities	8362078	USD
CY2016Q3	us-gaap	Liabilities Liabilities	10597364	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30082374	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22228777	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2269398	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1733437	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	4133905	USD
CY2016Q3	us-gaap	Long Term Debt LongTermDebt	6523051	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14606377	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8820806	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-169750	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4015	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13223771	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16123449	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-3401255	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7980831	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-4797825	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15760741	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	3745889	USD
	us-gaap	Operating Expenses OperatingExpenses	10234598	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	5472276	USD
	us-gaap	Operating Expenses OperatingExpenses	16792720	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3745889	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10234598	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5472276	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16792720	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	94094	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	75000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	81000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	68432	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	25662	USD
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	50100000	USD
CY2016Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	62800000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	797425	USD
CY2016Q3	us-gaap	Other Assets Current OtherAssetsCurrent	631225	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169750	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4015	USD
CY2015Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1115657	USD
CY2016Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1614835	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14500000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	691187	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	372011	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	376026	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	180922	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	126718	USD
CY2016Q3	us-gaap	Rental Properties RentalProperties	8063	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2662373	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7028242	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4563896	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13734693	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	9400	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74137740	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89898481	USD
CY2015Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2016Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	666123	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	759424	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	260000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.938
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.827
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.013
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	12000000	shares
CY2005Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	217630	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1937750	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10719904	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12440024	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.18
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.04
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9131823	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.20
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.45
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y5M27D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y8M19D
CY2016Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.33
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	642210	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	21720296	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	11631413	USD
CY2015Q4	us-gaap	Supplies Supplies	1158632	USD
CY2016Q3	us-gaap	Supplies Supplies	1037291	USD
CY2016Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4165567	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5349725	USD
CY2015Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	4197375	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	597719	USD
CY2015Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2555735	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1958775	USD
CY2016Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2340876	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90260703	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86156805	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	121336020	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101904347	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</font><font style="font-family:inherit;font-size:10pt;"> - Certain prior year amounts included in the prior year consolidated financial statements have been reclassified to conform to the current year presentation.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font><font style="font-family:inherit;font-size:10pt;">– The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-021194-index-headers.html	Edgar Link	pending
0001628280-16-021194-index.html	Edgar Link	pending
0001628280-16-021194.txt	Edgar Link	pending
0001628280-16-021194-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
imuc-20160930.xml	Edgar Link	completed
imuc-20160930.xsd	Edgar Link	pending
imuc-20160930_cal.xml	Edgar Link	unprocessable
imuc-20160930_def.xml	Edgar Link	unprocessable
imuc-20160930_lab.xml	Edgar Link	unprocessable
imuc-20160930_pre.xml	Edgar Link	unprocessable
imuc-93016x10q.htm	Edgar Link	pending
imuc-93016xexhibit1011.htm	Edgar Link	pending
imuc-93016xexhibit311.htm	Edgar Link	pending
imuc-93016xexhibit312.htm	Edgar Link	pending
imuc-93016xexhibit321.htm	Edgar Link	pending
imuc-93016xexhibit322.htm	Edgar Link	pending
imuc-93016xexhibit412.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

2016 Q4 Form 10-Q Financial Statement

#000162828016021194 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC EOM Pharmaceutical Holdings, Inc. Stock $imuc

2016 Q4 Form 10-Q Financial Statement

#000162828016021194 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc